Document:

Exhibit 10.23

 Exhibit 10.23 
  
 CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant to a request for confidential treatment and,
where applicable, have been marked with an asterisk (“[****]”) to denote where omissions have been made. The confidential material has been filed separately with the Securities and Exchange Commission. 
  
 LICENSE AGREEMENT 
  
 UNITED STATES OF AMERICA 
  
 LUNA TECHNOLOGIES, INC. 
  
 NONEXCLUSIVE LICENSE AGREEMENT NO. DN-951 
  
 LICENSE EFFECTIVE DATE: 12/20/00 

 TABLE OF CONTENTS 
  

			
	 	  	Page No.

	 PREAMBLE
	  	 
		
	 ARTICLE I Definitions
	  	1
		
	 ARTICLE II License Grant
	  	4
		
	 ARTICLE III Sublicenses
	  	4
		
	 ARTICLE IV Term of License
	  	5
		
	 ARTICLE V Practical Application
	  	5
		
	 ARTICLE VI United States Manufacture
	  	5
		
	 ARTICLE VII Royalty and Payment
	  	5
		
	 ARTICLE VIII Reports
	  	7
		
	 ARTICLE IX Audit Rights
	  	8
		
	 ARTICLE X Marking
	  	8
		
	 ARTICLE XI Use of the NASA Name
	  	9
		
	 ARTICLE XII Disclaimer of Warranties
	  	9
		
	 ARTICLE XIII Risk Allocation and Indemnification
	  	10
		
	 ARTICLE XIV Patent Validity
	  	11
		
	 ARTICLE XV Points of Contact
	  	12
		
	 ARTICLE XVI Notices
	  	12
		
	 ARTICLE XVII Nonassertion
	  	13
		
	 ARTICLE XVIII Disputes
	  	13
		
	 ARTICLE XIX Breach
	  	14
		
	 ARTICLE XX Termination
	  	15
		
	 ARTICLE XXI Assignment
	  	16

  

 -i- 

			
	 	  	Page No.

	 ARTICLE XXII Governing Law
	  	17
		
	 ARTICLE XXIII Independent Entities
	  	17
		
	 ARTICLE XXIV Effect of Partial Invalidity
	  	17
		
	 ARTICLE XXV Nonwaiver
	  	18
		
	 ARTICLE XXVI Entire Agreement
	  	18
		
	 ARTICLE XXVII Article Headings
	  	18
		
	 ARTICLE XXVIII Counterparts
	  	18
		
	 ARTICLE XXIX Acceptance
	  	19

  

 -ii- 

 LICENSE AGREEMENT 
  
 PREAMBLE 
  
 This License Agreement (“Agreement”) is entered into between the National Aeronautics and Space Administration (NASA), an agency of the United
States, hereinafter referred to as LICENSOR, having its headquarters in Washington, D.C., and Luna Technologies, Inc., a corporation of the State of Delaware, having its principal place of business at P.O. Box 11704, Blacksburg, VA, 24062,
hereinafter referred to as LICENSEE, as of the date of execution of the last PARTY hereto. 
  
 WITNESSETH: 
  
 WHEREAS, under the authority of 35 U.S.C. § 200 et seq., the U.S. Department of Commerce has issued Patent Licensing Regulations (37 CFR § Part 404) specifying the terms and conditions upon which
licenses may be granted for inventions assigned to LICENSOR; and 
  
 WHEREAS, LICENSOR is the assignee of U.S. Patent Application No. 09/606,120 for an invention entitled “Single Laser Sweep Full S-Parameter Characterization of Fiber Bragg Gratings,” which was filed on June 15,
2000; and of U.S. Patent Application No. 09/648,529 for an invention entitled “High Precision Solid State Wavelength Monitor,” which was filed on August 22, 2000. 
  
 WHEREAS, LICENSEE, in consideration of the grant of a license under U.S. Patent Application No. 09/606,120, and
U.S. Patent Application No. 09/648,529, will pay royalties, make all necessary capital investments, and achieve PRACTICAL APPLICATION of the inventions; and, 
  
 WHEREAS, LICENSOR has determined that the granting of a license to LICENSEE under U.S. Patent Application
No. 09/606,120, and U.S. Patent Application No. 09/648,529, will provide the necessary incentive for LICENSEE to achieve the desired early PRACTICAL APPLICATION of the inventions and the granting of such license to LICENSEE will therefore
be in the public interest; 
  
 NOW, THEREFORE, in
accordance with said Patent Licensing Regulations, and in consideration of the foregoing and of the terms hereinafter contained in this Agreement, the LICENSOR and LICENSEE agree as set forth below: 
  
 ARTICLE I  
  
 Definitions 
  
 “ACCOUNTING PERIOD” shall mean the period for which
royalties are calculated. For this Agreement, the period is every twelve (12) months beginning on January 1st and ending on December 31st of each calendar year. The first ACCOUNTING PERIOD for this Agreement commences on the LICENSE
COMMENCEMENT DATE and ends on December 31, 2001. 

 “BREACH” shall mean (a) a violation or nonperformance by a PARTY of a MATERIAL
term, condition, covenant or warranty herein, or (b) a misrepresentation made hereunder or in the inducement by LICENSEE to LICENSOR to enter into this Agreement (also see “MATERIAL”). 
  
 “BREACHING PARTY” shall mean the PARTY in BREACH, as used in
ARTICLE XIX. 
  
 “GROSS SALES” shall mean
the total amount invoiced by or for LICENSEE, and equivalent dollar value sum of all disposals i.e., (sales, uses, including uses by LICENSEE, leases, transfers, etc.) of ROYALTY-BASE PRODUCTS and ROYALTY-BASE SERVICES for monetary consideration
determined in, or as if in, an arm’s length transaction. 
  
 “INSOLVENT” shall mean that LICENSEE has ceased to pay its debts (which may include failure to pay royalty payments under this Agreement) in the ordinary course of business or cannot pay its debts as they fall due or is
insolvent within the meaning of the Federal Bankruptcy Code (11 U.S.C. § 101 (31)). 
  
 “LICENSE COMMENCEMENT DATE” shall mean the date that the last PARTY has executed this Agreement. 
  
 “LICENSE EXPIRATION DATE” shall mean the date the first
LICENSED PATENT(S) expires, or the date of abandonment of the last to be abandoned of any LICENSED PATENT APPLICATION(S), whichever is later, unless this Agreement is revoked or terminated in accordance with other provisions of this Agreement.

  
 “LICENSE TERM” shall mean the period of time
starting with the LICENSE COMMENCEMENT DATE and ending with the LICENSE EXPIRATION DATE. 
  
 “LICENSED AREA” shall mean the world. 
  
 “LICENSED FIELD” shall mean optical components, instrument, or systems for telecommunications, computers, or measurement. 
  
 “LICENSED INVENTION(S)” shall mean the invention(s) defined by the claims of the LICENSED PATENT(S) and as
may be further limited by ARTICLE II. 
  
 “LICENSED
PATENT(S)” shall mean all patents that issue from the LICENSED PATENT APPLICATION(S), and shall include any corresponding: reissue patents; modifications of said LICENSED PATENTS by means of certificates of correction or reexamination
certificates; and any National or Regional Patent(s). 
  
 “LICENSED PATENT APPLICATION(S)” shall mean U.S. Patent Application No. 09/606,120 and/or U.S. Patent Application No. 09/648,529; any national or regional Patent Application(s) that rely on PCT Patent Application
Numbers PCT/USOO/23588 and PCT/USOO/27454, and shall include any corresponding: continuation or divisional patent applications derived therefrom. 
  

 -2- 

 “MATERIAL,” with respect to a particular matter (e.g., a BREACH), shall mean that the
matter is shown to effect adversely (a) the rights and benefits of the other PARTY under this Agreement; or (b) the ability of the other PARTY to perform its obligations hereunder; and, in either case, to such a degree that a reasonable
person in the management of his or her own affairs would be more likely than not to decline to enter into this Agreement in view of the matter in question. 
  
 “NET SALES” shall mean GROSS SALES, less allowances for returns and less (to the extent separately stated, and not charged to the
customer or others, on the invoices): (1) regular trade and quantity discounts; (2) insurance and shipping charges from the point of origin; (3) duties, tariffs, and other customs charges; and (4) sales, use, and similar taxes.
In the case of a sale or other disposition of ROYALTY-BASE PRODUCTS which are transferred to a purchaser who does not deal at arm’s length, or transferred or otherwise disposed of for other than monetary consideration (including allocations to
LICENSEE’s own beneficial use), NET SALES shall be calculated in accordance with Section 7.5 of this Agreement. 
  
 “NONBREACHING PARTY” shall mean the PARTY not in BREACH, as used in ARTICLE XIX. 
  
 “PARTY” shall mean a party to this Agreement. 
  
 “PERSON” shall mean a natural person; a corporation (for
profit or not-for-profit); an association; a partnership (general or limited); a joint venture; a trust; a government or political department, subdivision, or agency; or any other entity. 
  
 “PRACTICAL APPLICATION” shall mean, with respect to the LICENSED INVENTION(S), to reduce it to practice and
to commercialize it, i.e., to manufacture it in the case of a composition or product, to practice it in the case of a process or method, or to operate it in the case of a machine or system; and, in each case, under such conditions as to establish:
(1) that a market for the LICENSED INVENTION(S) has been created, and to the extent practicable, that a market has been created in the United States; (2) that it is being utilized; (3) that its benefits are, to the extent permitted by
law or Government regulations, available to the public on reasonable terms; and (4) that market demand, at least in the United States, shall be reasonably met. 
  
 “ROYALTY-BASE PRODUCTS” shall include: (1) the components of an item sold, used, leased, transferred,
or otherwise disposed of by LICENSEE that are covered by or included within the LICENSED INVENTION(S); and (2) other components of the item not covered by or within the LICENSED INVENTION(S) that LICENSEE would not have sold, used, leased,
transferred, or otherwise disposed of but for the sale, use, lease, transfer, or other disposition of the LICENSED INVENTION(S). 
  
 “ROYALTY-BASE SERVICES” shall include any services sold, used, leased, transferred, or otherwise disposed of by LICENSEE or its agents
that use or employ the LICENSED INVENTION(S). Such ROYALTY-BASE SERVICES shall not include any services of the LICENSEE directly related to the initial installation and setup, including training or software installation, or to the repair of a
ROYALTY-BASE PRODUCT purchased by a THIRD PARTY. 
  

 -3- 

 “THIRD PARTIES” shall mean PERSONS other than the LICENSOR and the LICENSEE. 

 
 ARTICLE II 
  
 License Grant 
  
 2.1 LICENSOR hereby grants to LICENSEE a terminable, royalty-bearing, nonexclusive license to practice, i.e., to make, have made, use, sell, offer for
sale, import, transfer, or dispose of, the LICENSED INVENTION(S) as limited to the LICENSED AREA and the LICENSED FIELD, as defined in ARTICLE I. 
  
 2.2 LICENSOR, upon request, agrees to grant LICENSEE a license to practice any inventions assigned to LICENSOR, without which license or licenses, the
practice of the LICENSED INVENTION(S) would result in infringement. The grant of said license or licenses shall be limited, however, to the extent necessary to practice the LICENSED INVENTION(S). There will be no such grant where said inventions are
licensed exclusively. 
  
 2.3 Notwithstanding anything to the
contrary in this Agreement, LICENSEE shall take the license granted in this ARTICLE II subject to any outstanding licenses or other rights in THIRD PARTIES under Agreements executed by LICENSOR prior to the LICENSE COMMENCEMENT DATE.

  
 2.3 LICENSOR reserves an irrevocable, royalty-free right to
practice and have practiced the LICENSED INVENTION(S), and any other inventions as provided in Section 2.2, throughout the world by or on behalf of the Government of the United States and on behalf of any foreign government pursuant to any
existing or future treaty or Agreement with the United States. 
  
 2.5 NASA intends to file timely National or Regional Patent Applications corresponding to PCT Application Numbers PCT/USOO/23588, entitled “Single Laser Sweep Full S-Parameter Characterization of Fiber Bragg Gratings” and
PCT/USOO/27454, entitled “High Precision Solid State Wavelength Monitor” after being timely notified in writing of the selected countries designated by the LICENSEE. To conserve costs, NASA also intends to file such applications directly
through foreign associates. LICENSEE agrees to pay timely the foreign associate, upon receipt of billing, the official fees (including maintenance fees) and the foreign associate’s fees for assisting in prosecution of the National or Regional
Patent Application. 
  
 ARTICLE III  
  
 Sublicenses 
  
 3.1 LICENSEE shall not have the right to grant sublicenses. 
  

 -4- 

 ARTICLE IV  
  
 Term of License 
  
 4.1 The license granted in ARTICLE II will be in effect for the LICENSE TERM. Except as may be expressly provided otherwise herein or agreed to in
writing by LICENSOR, the license shall expire automatically at the end of the LICENSE TERM without notice to LICENSEE. In the event the LICENSE TERM will expire before the expiration of the LICENSED PATENT(S), LICENSEE may request extension of the
LICENSE TERM before the expiration of the LICENSE TERM. 
  
 ARTICLE
V 
  
 Practical Application 
  
 5.1 LICENSEE shall achieve PRACTICAL APPLICATION of the LICENSED INVENTION(S)
within [****] of the LICENSE COMMENCEMENT DATE. 
  
 5.2 LICENSEE, once PRACTICAL APPLICATION of the LICENSED INVENTION(S) is achieved, shall thereafter maintain it throughout the LICENSE TERM. 
  
 ARTICLE VI  
  
 United States Manufacture 
  
 6.1 LICENSEE shall both reduce the LICENSED INVENTION(S) to practice and substantially manufacture the LICENSED INVENTION(S) in the United States. 
  
 6.2 LICENSEE shall make a bona fide attempt to use or sell the LICENSED INVENTION(S) in the United States. 
  
 6.3 LICENSEE shall promptly report to LICENSOR its discontinuance of making
the benefits of the LICENSED INVENTION(S) available to the public. 
  
 6.4 Failure to comply with the terms of this ARTICLE shall be cause for unilateral modification or termination of this Agreement in accordance with ARTICLE XX. 
  
 ARTICLE VII  
  
 Royalty and Payment 
  
 7.1 In consideration of the license granted in ARTICLE II, LICENSEE shall remit to LICENSOR a nonrefundable license fee in the amount of
[****] upon the execution of this Agreement by LICENSEE. 
  

 -5- 

 7.2 LICENSEE agrees to pay LICENSOR a running royalty of [****] of the NET SALES of ROYALTY-BASE
PRODUCTS and ROYALTY-BASE SERVICES. The running royalty shall be remitted to LICENSOR annually, within THIRTY (30) days of the end of each ACCOUNTING PERIOD. 
  
 7.3 LICENSEE agrees to pay LICENSOR the following annual minimum guaranteed royalties according to the following payment
schedule: 
  
 End Of the second ACCOUNTING
PERIOD: [****] 
  
 End of the third
ACCOUNTING PERIOD: [****] 
  
 End of the
fourth ACCOUNTING PERIOD: [****] 
  
 End
of the fifth and each subsequent ACCOUNTING PERIOD: [****] 
  
 The minimum royalty shall be remitted within THIRTY (30) days of the end of each ACCOUNTING PERIOD. 
  
 7.4 The minimum royalty specified in Section 7.3 shall not be due for any particular ACCOUNTING PERIOD if the running royalties specified in
Section 7.2 are equal or greater than the minimum royalty. 
  
 7.5 To ensure that LICENSOR receives all royalty payments due under this Agreement, LICENSEE agrees that in the event any ROYALTY-BASE PRODUCTS shall be sold, transferred, or disposed of for purposes of resale (a) to any type of
organization or individual who owns a controlling interest in LICENSEE by stock ownership or otherwise, (b) to any type of organization in which LICENSEE shall own, directly or indirectly, a controlling interest by stock ownership or otherwise,
or (c) to any type of organization with which, or individual with whom, LICENSEE, its stockholders, or associated companies shall have any agreement, understanding, or arrangement (such as, among other things, an option to purchase stock, an
arrangement involving a division of profits, or special rebates or allowances) without which agreement, understanding, or arrangement, prices paid by such organization or individual for the ROYALTY-BASE PRODUCTS would be higher than the NET SALES
reported by LICENSEE, or if such agreement, understanding, or arrangement, results in extending to such organization or individual lower prices for ROYALTY-BASE PRODUCTS than those charged to outside concerns buying similar merchandise in similar
amounts and under similar conditions, then, and in all similar events, the royalties to be paid under this Agreement for the ROYALTY-BASE PRODUCTS shall be based upon the NET SALES at which the purchaser of the ROYALTY-BASE PRODUCTS resells the
ROYALTY-BASE PRODUCTS, rather than upon the NET SALES of LICENSEE. 
  
 7.6 Under this Agreement, ROYALTY-BASE PRODUCTS and ROYALTY-BASE SERVICES will be considered sold when invoiced, shipped, or paid, whichever occurs first. 
  
 7.7 Royalties shall be paid within THIRTY (30) days of the end of each ACCOUNTING PERIOD. Royalties shall be paid by
check, denominated in United States dollars, and made payable to the National Aeronautics and Space Administration. The check shall be mailed to LICENSOR at the address set forth in ARTICLE XV of this Agreement concurrently with the report
required in ARTICLE VIII of this Agreement. 
  

 -6- 

 7.8 LICENSOR shall assess interest, penalties, and administrative costs in accordance with the Federal
Claims Collections Standards, 4 CFR §§ 100-105, on all payments due LICENSOR which are not timely paid by LICENSEE. 
  
 ARTICLE VIII  
  
 Reports 
  
 8.1 LICENSEE shall submit to LICENSOR written reports within THIRTY (30) days of the end of every ACCOUNTING PERIOD whether or not royalties are due. Each report shall be submitted concurrently with the royalties required by
ARTICLE VII. 
  
 8.2 Each report shall include the following
information: 
  
 (a) A narrative description of the steps being
taken to reduce the LICENSED INVENTION(S) to practice. 
  
 (b) A
narrative description of the steps being taken to create a market demand for the LICENSED INVENTION(S), to commercialize the LICENSED INVENTION(S), and to meet market demand for the LICENSED INVENTION(S). 
  
 (c) A narrative description of the ROYALTY-BASE PRODUCTS and ROYALTY-BASE
SERVICES currently being offered for sale by LICENSEE. Copies of current sales brochures, promotional materials, and price lists shall be included with this description. 
  
 (d) A list of the geographic locations at which the LICENSED INVENTION(S) is being manufactured. 
  
 (e) The number and type of ROYALTY-BASE PRODUCTS sold or disposed of by
LICENSEE. 
  
 (f) The number and type of ROYALTY-BASE PRODUCTS
sold or disposed of by each reseller of ROYALTY-BASE PRODUCTS under Section 7.5. 
  
 (g) LICENSEE’S GROSS SALES. 
  
 (h) GROSS SALES for each reseller of ROYALTY-BASE PRODUCTS under Section 7.5. 
  
 (i) LICENSEE’S NET SALES. 
  
 (j) NET SALES for each reseller of ROYALTY-BASE PRODUCTS under Section 7.5. 
  

 -7- 

 (k) The amount of royalties due LICENSOR. 
  
 8.3 Each report shall be accompanied by a certification by an officer of LICENSEE that the LICENSEE is complying with the
terms and conditions of this Agreement and that the responses to each part of Section 8.2 are accurate and complete. 
  
 8.4 LICENSEE shall, on an annual basis, submit to LICENSOR an audited balance sheet and an audited income statement. Internal audits are permissible, but
LICENSOR reserves the right to require an independent audit and additionally reserves the right to approve of the auditor. 
  
 8.5 LICENSEE shall submit a final report to LICENSOR within THIRTY (30) days after the termination of this Agreement. 
  
 ARTICLE IX  
  
 Audit Rights 
  
 9.1 LICENSEE shall keep full, true, and accurate records for the purpose of
LICENSOR verifying LICENSEE’S reports to LICENSOR under ARTICLE VIII, verifying LICENSEE’S royalty payments to LICENSOR under ARTICLE VII, and for determining LICENSEE’S activities in general under the Agreement. These
records shall include, but are not limited to, ledgers and journals of account, customer orders, invoices, shipping documents, inventory records, computer records, purchase orders, and tax records. These records, as a whole, shall include
information which will allow, at a minimum, identification of suppliers, customers, items sold or otherwise transferred, and/or services rendered, as well as whether the LICENSEE is operating within the scope of its license. 
  
 9.2 The records described in Section 9.1 shall be available for audit by
LICENSOR, or by an authorized representative of LICENSOR, at all reasonable times for the LICENSE TERM and for three (3) calendar years thereafter. In addition, LICENSEE shall permit inspection by LICENSOR, or by an authorized representative of
LICENSOR, of LICENSEE’S assembly facilities and of LICENSEE’S inventory of ROYALTY-BASE PRODUCTS, including parts, works-in-progress, and finished goods, during any audit by LICENSOR. 
  
 9.3 If LICENSOR, as a result of an audit, discovers an underpayment of
royalties which exceeds [****] of the royalties due for a particular period, then LICENSEE shall reimburse LICENSOR for the cost of the audit, including all related costs of performing the audit (e.g., travel, food, lodging, cost of
professional services, etc.), in addition to any penalties assessed pursuant to Section 7.8. 
  
 ARTICLE X  
  
 Marking 
  
 10.1 LICENSEE shall mark all
ROYALTY-BASE PRODUCTS, or products incorporating ROYALTY-BASE PRODUCTS, in accordance with the statutes of the United States relating to the 
  

 -8- 

 marking of patented articles (see 35 U.S.C. § 287). Such marking shall be accomplished by fixing on the article
or when, from the character of the article, this cannot be done, by fixing to it, or to the package wherein one or more articles is contained, a label including the notation “Licensed from the National Aeronautics and Space Administration under
U.S. Patent No. X,XXX,XXX.” Such marking shall also be included into all literature and/or advertising materials describing the LICENSED INVENTION(S). 
  
 ARTICLE XI  
  
 Use of the NASA Name 
  
 11.1 Except as required by Section 10.1, LICENSEE may use the name of LICENSOR, or the acronym “NASA”, only in truthful statements concerning its relationship with LICENSOR. The letters “NASA”
may be used in such truthful statements only if they are: 
  
 (a)
used in their normal typed or printed form; 
  
 (b) the same size,
color, and intensity as the rest of the words in a sentence; 
  
 (c) not used in their stylized version as they appear in the NASA logotype insignia; and 
  
 (d) not used to indicate that NASA approves of the LICENSEE’S products, processes, etc. 
  
 11.2 Uses of the letters “NASA” and the words “National Aeronautics and Space Administration”, other
than those specified in Section 11.1, shall require the express written approval of LICENSOR. Approval by LICENSOR shall be based on applicable law (i.e., 42 U.S.C. §§ 2459(b), 2472(a), and 2473 (c)(l); and 14 CFR
§ 1221.100 et seq. ) and NASA policy governing the use of the words “National Aeronautics and Space Administration” and the letters “NASA”. 
  
 11.3 LICENSEE agrees to make copies of its marketing literature or items available to LICENSOR so that LICENSOR can
determine that such use is in accordance with the terms of this ARTICLE. 
  
 ARTICLE XII  
  
 Disclaimer of Warranties

  
 12.1 LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS,
IMPLIED, OR STATUTORY, AS TO ANY MATTER WHATSOEVER. 
  
 12.2 In
particular, nothing in this Agreement shall be construed as: 
  
 (a) A warranty or representation by LICENSOR as to the validity or scope of any LICENSED PATENT(S); or 
  

 -9- 

 (b) A warranty or representation that anything made, used, sold, or otherwise disposed of under any
license granted in this Agreement is or will be free from infringement of any type, including patent infringement, copyright infringement, and trademark infringement; or 
  
 (c) A requirement that LICENSOR shall file any patent application, secure any patent, or maintain any patent in force, other
than the LICENSED PATENT(S); or 
  
 (d) An obligation to bring or
prosecute actions or suits against THIRD PARTIES for infringement; or 
  
 (e) An obligation to furnish any manufacturing or technical information; or, if any such information is supplied, a warranty or representation that such information is accurate; or 
  
 (f) Conferring a right to use in advertising, publicity or otherwise the name
of any inventor of the LICENSED INVENTION(S) or the NASA name, seal, insignia, logotype insignia or any other adaptation without the prior written consent of LICENSOR (except as otherwise provided in ARTICLE XI); or 
  
 (g) Precluding the export from the United States of ROYALTY-BASE PRODUCTS on
which royalties shall have been paid as provided in ARTICLE VII, provided that the item can be exported under the export control laws of the United States; or 
  
 (h) Granting by implication, estoppel, or otherwise, any licenses or other rights under any other patent of LICENSOR (or any
other PERSON in the United States or any foreign country); or 
  
 (i) Granting by implication, estoppel, or otherwise, any licenses or rights under other patents or patent applications of LICENSOR other than as provided by this Agreement in Section 2.2, regardless of whether such other patents or
patent applications are dominant, subordinate, or an improvement to the inventions as claimed, of the LICENSED PATENT(S) or LICENSED PATENT APPLICATIONS), nor to other applications that did not claim the inventions. 
  
 (j) Conferring upon any PERSON (1) any immunity from or defenses under
the antitrust laws, (2) any immunity from a charge of patent misuse, or (3) any immunity from the operation of Federal, State, or other lax. 
  
 ARTICLE XIII  
  
 Risk Allocation and Indemnification 
  
 13.1 LICENSOR makes no representation, extends no warranties of any kind, either express or implied, and assumes no responsibility whatsoever with respect
to use, sales, or other disposition by LICENSEE or its vendees or other transferees of products incorporating or made by the use of (1) the LICENSED INVENTION(S) or (2) information, if any, furnished under this Agreement. 
  

 -10- 

 13.2 LICENSEE shall indemnify LICENSOR, its officers and employees, and hold them harmless against all
liabilities, demands, damages, expenses, or losses including, but not limited to, attorney’s fees, court costs, and the like, arising (1) out of the use by LICENSEE or its transferees of the LICENSED INVENTION(S) or information furnished
under this Agreement, or (2) out of any sale, use, or other disposition by LICENSEE or its transferees of products, processes, or compositions, made by use of such inventions or information. 
  
 13.3 It shall be the sole responsibility of the LICENSEE to ensure that any
and all embodiments of the LICENSED INVENTION(S) are safe under all circumstances. 
  
 13.4 Independent of, severable from, and to be enforced independently of any other enforceable or unenforceable provision of this Agreement, other than as provided in Sections 13.1 and 13.2, or other than for
infringement of one PARTY’S intellectual property rights by another PARTY, (including any engagement in licensable activities by licenses beyond the scope of the license provided by this Agreement), neither PARTY will be liable to the other
PARTY (nor to any THIRD PARTY claiming rights derived from the other PARTY’S rights) for incidental, consequential, special, punitive, or exemplary damages of any kind, including lost profits, loss of business, or other economic damage, and
further including injury to property, as a result of breach of any warranty or other term of this Agreement, regardless of whether the PARTY liable or allegedly liable was advised, had reason to know, or in fact knew of the possibility thereof.

  
 ARTICLE XIV  
  
 Patent Validity 
  
 14.1 If, in any proceeding in which the validity, infringement, or priority
of invention of any claim of the LICENSED PATENT(S) to LICENSEE is in issue, a judgment or decree is entered which becomes final (below referred to as an “final judgment”), the construction placed upon any such claim by such final judgment
shall thereafter be followed, not only as to such claim but as to all claims to which such construction applies, with respect to subsequently occurring acts. If such final judgment holds any claim invalid, LICENSEE shall be relieved prospectively
(1) from including in its reports ROYALTY-BASE PRODUCTS and ROYALTY-BASE SERVICES sold or otherwise disposed of covered only by such claim or any broader claim to which such final judgment is applicable, and (2) from the performance of
those other acts which may be required by this Agreement only because of any such claim. However, if there are two or more conflicting final judgments with respect to the same claim based on the same grounds or where the same issues were raised, the
decision of the higher tribunal shall be followed, but if the tribunals be of equal dignity, then the decision more favorable to the claim shall be followed. 
  
 14.2 In the event evidentiary material comes to the attention of the LICENSEE subsequent to the LICENSEE’S execution of this Agreement which, in the
judgment of the LICENSEE, bears on the validity or scope of any LICENSED PATENT(S), the LICENSOR will in good faith discuss with the LICENSEE whether such evidentiary material so affects the validity or scope of the LICENSED PATENT(S) to which it is
asserted to apply that the terms of the license in respect to such LICENSED PATENT(S) should be modified. 
  

 -11- 

 14.3 The LICENSEE, subsequent to the date of its execution of this Agreement, may assert the invalidity
of any claim in any LICENSED PATENT(S), if coupled with or followed by: 
  
 (a) withholding, or notice of intention to withhold, or denial of obligation to pay, royalties otherwise payable under this Agreement in respect to the LICENSEE’S operations under such claim; or 
  
 (b) initiation or participation in a suit challenging or denying the validity
of such claim in reference to LICENSEE’S operations under this Agreement, that may, at the option of the LICENSOR, be conclusively presumed to constitute LICENSEE’S termination, as of the earliest provable date of such withholding, notice,
denial, initiation, or participation, of its Agreement including its obligation for payment of royalties due from the date of the termination. 
  
 14.4 If an action by a THIRD PARTY requires the LICENSEE to defend its right to practice the LICENSED PATENT(S) pursuant to this Agreement, then LICENSOR
may, in its sole discretion, cooperate and assist in all respects and, to the extent possible, make available relevant records, papers, information, samples, models, specimens; and the like. 
  
 ARTICLE XV  
  
 Points of Contact 
  
 15.1 The following individuals are designated as the points of contact for
their respective PARTY. These points of contact are the principal representatives of the PARTIES involved in the performance of this Agreement. 
  

			
	 LICENSOR

	 	 LICENSEE

		
	 NASA Langley Research Center
	 	 Luna Technologies, Inc.

	 Patent Counsel Office
	 	 Douglas B. Juanarena,

	 3 Langley Blvd.
	 	 President/CEO

	 Mail Stop 212
	 	 2851 Commerce Street SE

	 Hampton, VA 23681-2199
	 	 Blacksburg, VA 26040

	 Telephone No.: [****]
	 	 Telephone No.: [****]

	 Facsimile No.: [****]
	 	 Facsimile No.: [****]

  
 ARTICLE XVI 

  
 Notices 
  
 16.1 Notices hereunder will be delivered and effective as follows:

  
 (a) Every notice required or contemplated by this Agreement
to be given either PARTY may be delivered in person or may be sent by courier, telecopy, express mail, telex, telegraph or postage prepaid certified or registered air mail (or its equivalent under the laws of the country where mailed), addressed to
the PARTY for whom it is intended, at the address specified in ARTICLE XV. Either PARTY may change its address for notice by giving notice to the other PARTY of the change. 
  

 -12- 

 (b) Any written notice will be effective no earlier than the date delivered. 
  
 (c) Unless otherwise provided in this Agreement, notice by courier, or by
express, certified, or registered mail, will be effective on the date it is officially recorded as delivered by return receipt or the equivalent, and in the absence of such record as to delivery, it will be rebuttably presumed to have been delivered
on the fifth business day after it was deposited, first-class postage prepaid, in the mail. 
  
 (d) Notice by telex or telegraph will be deemed given at the time it is recorded by the carrier in the ordinary course of business as having been delivered, but in any event no later than one business day after
dispatch. 
  
 (e) Notice not given in writing will be effective
only if acknowledged in writing by a duly authorized officer of the PARTY to whom it was given. 
  
 (f) As used in this ARTICLE, a reference to a particular date means the date itself, if a business day, otherwise the first business day after the date.

  
 ARTICLE XVII  
  
 Nonassertion 
  
 17.1 LICENSOR agrees not to assert any of its rights under any others of its
patents against LICENSEE or its transferees, which rights are necessary to the practice of rights granted to LICENSEE under this Agreement. 
  
 ARTICLE XVIII  
  
 Disputes 
  
 18.1 All disputes concerning the interpretation or application of this Agreement shall be discussed mutually between the PARTIES. Any disputes which are not disposed of by mutual Agreement shall be decided by the NASA Associate General
Counsel (Intellectual Property), or designee, who shall reduce the decision to writing and mail or otherwise furnish a copy thereof to LICENSEE. The decision shall be final and conclusive, unless within THIRTY (30) days from the date of receipt
of such decision, LICENSEE mails or otherwise furnishes a written appeal addressed to the Administrator, National Aeronautics and Space Administration, Washington, DC 20546. LICENSEE shall be afforded an opportunity to be heard and to offer evidence
in support of its appeal. The NASA Administrator, or designee, shall make the decision on the appeal, which shall be the final agency decision from which there will be no further right of administrative appeal. 
  

 -13- 

 ARTICLE XIX  
  
 Breach 
  
 19.1 In the event of a BREACH of any warranty, covenant, or other provision of this Agreement, the following notice and cure procedures, if the BREACH is
curable, shall apply. 
  
 19.2 The NONBREACHING PARTY shall give
the BREACHING PARTY notice describing the BREACH and stating the time, as provided below, within which the BREACH must be cured. 
  
 19.3 If a provision of this Agreement sets forth a cure period for the BREACH in question, then that provision shall take precedence over any cure period
set forth in this ARTICLE. 
  
 19.4 No cure period is required,
except as may be otherwise provided in this Agreement, if: 
  
 (a) this Agreement sets forth specific deadline dates for the obligation allegedly breached; or 
  
 (b) this Agreement otherwise states that no cure period is required in connection with the termination in question. 
  
 19.5 If the BREACH is of an obligation to pay money, or a nonwillful curable
BREACH of an obligation of the BREACHING PARTY relating to the NONBREACHING PARTY’S intellectual property rights, then the BREACHING PARTY shall have FIVE (5) business days to cure the BREACH after written notice of such BREACH by the
BREACHING PARTY. 
  
 19.6 If the BREACH is willful and of an
obligation of the BREACHING PARTY relating to the NONBREACHING PARTY’S intellectual property rights, then the NONBREACHING PARTY may, in its sole discretion, specify in the notice of BREACH that no cure period will be permitted. 
  
 19.7 If the BREACH is other than a BREACH of the kind described above in this
ARTICLE, then the cure period will be THIRTY (30) days after the effective date of notice of the BREACH from the NONBREACHING PARTY. 
  
 19.8 The BREACHING PARTY will be deemed to have cured such BREACH if within the cure period it takes steps reasonably adequate to alleviate any damage to
the NONBREACHING PARTY resulting from the BREACH and to prevent a similar future BREACH. 
  
 19.9 If a BREACH has not been cured at the end of its cure period, if any, then this Agreement may be terminated upon expiration of the cure period as provided by ARTICLE XX. 
  

 -14- 

 ARTICLE XX  
  
 Termination 
  
 20.1 The PARTIES may terminate or modify this Agreement by mutual consent upon such terms as they may agree in writing. 
  
 20.2 Either PARTY may terminate this Agreement by failing to extend the
LICENSE TERM. 
  
 20.3 Either PARTY may terminate this Agreement
upon the discovery by that PARTY of any intentional MATERIAL false statement or other intentional MATERIAL misrepresentation made or submitted to that PARTY, by the other PARTY, which BREACHES any obligation under the terms of this Agreement.

  
 20.4 Either PARTY may terminate this Agreement upon any
failure by the other PARTY to provide, within TEN (10) business days after notice, satisfactory and adequate assurances to the terminating PARTY that the other PARTY is able and willing to fully and effectively perform its obligations under
this Agreement. 
  
 20.5 LICENSEE may prospectively terminate this
Agreement as a whole, as well as any concomitant future obligations evidenced in writing executed after the LICENSE COMMENCEMENT DATE, with respect to any LICENSED PATENT(S) upon ninety (90) days written notice to LICENSOR. 
  
 20.6 This Agreement may be terminated by LICENSOR if: 
  
 (a) LICENSOR determines that LICENSEE has failed or will fail to achieve
PRACTICAL APPLICATION of the LICENSED INVENTION(S) as provided by Section 5.1. 
  
 (b) LICENSOR determines that LICENSEE has failed or will fail to maintain PRACTICAL APPLICATION of the LICENSED INVENTION(S) as provided by Section 5.2. 
  
 (c) LICENSOR determines that LICENSEE has failed or will fail to both reduce
to practice and manufacture the LICENSED INVENTION(S) in the United States as provided by Section 6.1. 
  
 (d) LICENSOR determines that LICENSEE has failed or will fail to meet market demand for the LICENSED INVENTION(S) as provided by ARTICLE V.

  
 (e) LICENSEE fails to pay royalties as provided by
ARTICLE VII. 
  
 (f) LICENSEE fails to submit reports as
provided by ARTICLE VIII. 
  
 (g) LICENSEE fails to pay
royalties sufficient to cover the patent maintenance fees due on the LICENSED PATENT(S) for each of the years that patent maintenance fees are due. 
  
 (h) LICENSOR determines that such action is necessary to meet the requirements for public use specified by Federal regulations issued after the LICENSE
COMMENCEMENT DATE and LICENSEE does not reasonably satisfy such requirements. 
  

 -15- 

 (i) LICENSEE commits a MATERIAL BREACH of a covenant or term contained in this Agreement. 
  
 20.7 LICENSOR may terminate this Agreement if LICENSEE becomes
“INSOLVENT.” LICENSEE must notify LICENSOR within THIRTY (30) days after becoming INSOLVENT. LICENSEE’S failure to conform to this requirement shall be deemed a material, incurable breach. 
  
 20.8 LICENSEE must promptly inform LICENSOR of its intention to file a
voluntary petition in bankruptcy or of another’s communicated intention to file an involuntary petition in bankruptcy. LICENSOR may terminate this Agreement upon receiving notice of intention to file. LICENSEE’S filing without conforming
to this requirement shall be deemed a material, pre-petition incurable breach. 
  
 20.9 Before LICENSOR modifies or terminates this Agreement for any cause, LICENSOR will furnish to LICENSEE a written notice stating LICENSOR’S intention to modify or terminate the Agreement and the reasons
therefor. LICENSEE will be allowed THIRTY (30) days after receipt of such notice to remedy any BREACH of the Agreement or show cause why the Agreement should not be terminated. A response to such notice should be addressed to the General
Counsel, National Aeronautics and Space Administration, Washington, DC 20546. 
  
 20.10 LICENSEE may directly appeal in writing, within THIRTY (30) days of receipt of the notice stating LICENSOR’S intention to modify or terminate the Agreement, to the NASA Administrator on the question of
whether the Agreement should be terminated. If reconsideration of the intention to terminate the Agreement has been requested under Section 20.9, then LICENSEE may appeal to the NASA Administrator within THIRTY (30) days after receiving
notice of an adverse decision or determination from the NASA General Counsel. The notice of appeal and all supporting documentation should be addressed to the Administrator, National Aeronautics and Space Administration, Washington, DC 20546.
LICENSEE shall be afforded an opportunity to be heard and to offer evidence in support of its appeal. The NASA Administrator, or designee, shall make the decision on the appeal, which shall be the final agency decision from which there will be no
further right of administrative appeal. 
  
 20.11 If no action is
taken under Sections 20.9 and 20.10, then the decision to modify or terminate this Agreement shall become final. 
  
 20.12 All royalties and reports due up to and including the date of termination of this Agreement are due within THIRTY (30) days of the date of
termination. 
  
 ARTICLE XXI  
  
 Assignment 
  
 21.1 LICENSEE may not assign or transfer this Agreement, and any purported
assignment or transfer shall be null and void and a BREACH of this Agreement. 
  

 -16- 

 ARTICLE XXII  
  
 Governing Law 
  
 22.1 This Agreement will be interpreted and enforced in accordance with United States federal law. 
  
 ARTICLE XXIII  
  
 Independent Entities 
  
 23.1 The Parties are separate and independent entities. Except as may be
expressly and unambiguously provided in this Agreement, no partnership or joint venture is intended to be employee relationship. 
  
 23.2 Except to the extent expressly provided in this Agreement, neither PARTY has, and neither PARTY shall attempt to assert, the authority to make
commitments for or to bind the other PARTY to any obligation. 
  
 ARTICLE XXIV  
  
 Effect of Partial
Invalidity 
  
 24.1 If any one or more of the provisions of
this Agreement should be ruled wholly or partly invalid or unenforceable by a court or other government body of competent jurisdiction, and as long as the fundamental objectives of the Agreement can be carried out, then: 
  
 (a) the validity and enforceability of all provisions of this Agreement not
ruled to be invalid or unenforceable will be unaffected; 
  
 (b)
the provision(s) held wholly or partly invalid or unenforceable will be deemed to be amended, and the court or other government body is authorized to reform the provision(s), to the minimum extent necessary to render them valid and enforceable in
conformity with the PARTIES’ intent as manifested herein; and 
  
 (c) if the ruling, and/or the controlling principle of law or equity leading to the ruling, is subsequently overruled, modified, or amended by legislative, judicial, or administrative action, then the provision(s) in question, as
originally set forth in this Agreement, will be deemed to be valid and enforceable to the maximum extent permitted by the new controlling principle of law or equity. 
  

 -17- 

 ARTICLE XXV  
  
 Nonwaiver 
  
 25.1 The failure of either PARTY at any time to require performance by the other PARTY of any provision of this Agreement shall in no way affect the right
of such PARTY to require future performance of such provision. Any waiver by either PARTY of any BREACH of any provision of this Agreement shall not be construed as a waiver of any continuing or succeeding BREACH of such provision, a waiver of the
provision itself, or a waiver of any right under this Agreement. 
  
 ARTICLE XXVI  
  
 Entire Agreement

  
 26.1 Except as may be expressly provided otherwise herein,
this Agreement constitutes the entire Agreement between the PARTIES concerning the subject matter thereof. No prior or contemporaneous representations, inducements, promises, or agreements, oral or otherwise, between the PARTIES with reference
thereto will be of any force or effect. This Agreement may only be modified by written agreement of the PARTIES. 
  
 ARTICLE XXVII  
  
 Article Headings 
  
 27.1
The ARTICLE headings contained in this Agreement are for reference purposes only and shall not in any way control the meaning or interpretation of this Agreement. 
  
 ARTICLE XXVIII  
  
 Counterparts 
  
 28.1 This Agreement may be executed in separate counterparts, each of which so executed and delivered shall constitute an original, but all such
counterparts shall together constitute one and the same instrument. Any such counterpart may comprise one or more duplicates or duplicate signature pages, any of which may be executed by less than all of the PARTIES, provided that each PARTY
executes at least one such duplicate or duplicate signature page. The PARTIES stipulate that a photostatic copy of an executed original will be admissible in evidence for all purposes in any proceeding as between the PARTIES. 
  

 -18- 

 ARTICLE XXIX  
  
 Acceptance 
  
 29.1 In witness whereof, each PARTY has caused this Agreement to be executed by its duly authorized representatives: 
  

							
	 LICENSOR:
	 	 	 	LICENSEE:
			
	 National Aeronautics and Space Administration
	 	 	 	 Luna Technologies, Inc.

				
	 By:
	 	 /s/    Edward A. Frankle

	 	 	 	 /s/    Douglas B. Juanarena

	 	 	 Edward A. Frankle
	 	 	 	 Douglas B. Juanarena

	 	 	 NASA General Counsel
	 	 	 	 President and CEO

			
	 Date: December 20, 2000
	 	 	 	 Date: December 6, 2000

  
 cc:

 Office of Patent Counsel 
 NAA Langley Research Center 
  

 -19-Exhibit 10.24

 Exhibit 10.24 
  
 CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant to a request for confidential treatment and,
where applicable, have been marked with an asterisk (“[****]”) to denote where omissions have been made. The confidential material has been filed separately with the Securities and Exchange Commission. 
  
 LICENSE AGREEMENT 
  
 UNITED STATES OF AMERICA 
  
 AND 
  
 LUNA INNOVATIONS INCORPORATED 
  

EXCLUSIVE LICENSE AGREEMENT DE-384 
  
 EFFECTIVE DATE: 10/28/04 

 TABLE OF CONTENTS 
  

					
	 ARTICLE

	  	PAGE NO.

	 	  	PREAMBLE	  	1
			
	 I
	  	Definitions	  	2
			
	 II
	  	License Grant	  	5
			
	 III
	  	Sublicenses	  	6
			
	 IV
	  	Term of License	  	7
			
	 V
	  	Practical Application	  	7
			
	 VI
	  	United States Manufacture	  	8
			
	 VII
	  	Royalty and Payment	  	8
			
	 VIII
	  	Reports	  	10
			
	 IX
	  	Audit Rights	  	11
			
	 X
	  	Marking	  	12
			
	 XI
	  	Use of the JOINT OWNERS’ Names and Disclosure	  	12
			
	 XII
	  	Disclaimer of Warranties	  	13
			
	 XIII
	  	Risk Allocation and Indemnification	  	14
			
	 XIV
	  	Patent Validity	  	15
			
	 XV
	  	Points of Contact	  	16
			
	 XVI
	  	Notices	  	17
			
	 XVII
	  	Infringement	  	17
			
	 XVIII
	  	Dispute or Breach	  	18
			
	 XIX
	  	Termination or Modification	  	19
			
	 XX
	  	Assignment	  	21

  

 -i- 

					
			
	 XXI
	  	Governing Law	  	21
			
	 XXII
	  	Independent Entities	  	21
			
	 XXIII
	  	Effect of Partial Invalidity	  	21
			
	 XXIV
	  	Nonwaiver	  	22
			
	 XXV
	  	Entire Agreement	  	22
			
	 XXVI
	  	Article Headings	  	22
			
	 XXVII
	  	Counterparts	  	23
			
	 XXVIII
	  	Acceptance	  	23
			
	 	  	APPENDIX A	  	24
			
	 	  	APPENDIX B	  	1

  

 -ii- 

 LICENSE AGREEMENT 
  
 PREAMBLE 
  
 This License Agreement (“AGREEMENT”) is entered into between the National Aeronautics and Space Administration (NASA), an agency of the United
States, hereinafter referred to as LICENSOR, having its headquarters at Washington, D.C., and Luna Innovations Incorporated, a corporation of the State of Delaware, having its principal place of business at 2851 Commerce Street, Blacksburg, VA
24060, hereinafter referred to as LICENSEE, as of the date of execution of the last PARTY hereto. 
  
 WITNESSETH: 
  
 WHEREAS, under the authority of 35 U.S.C. § 200 et seq., the U.S. Department of Commerce has issued Patent Licensing Regulations (37 CFR Part 404) specifying the terms and conditions upon which licenses may be
granted for inventions assigned to LICENSOR; and 
  
 WHEREAS, LICENSOR is the assignee of U.S. Patent No. 5,214,955 for an invention entitled “Constant Frequency Pulsed Phase-Lock Measuring Device,” which issued on June 1, 1993; U.S. Patent No. 5,150,620 for an
invention entitled “Method of Recertifying Load Bearing Member,” which issued on September 29, 1992; U.S. Patent No. 5,841,032 for an invention entitled “Variable and Fixed Frequency Pulsed Phase-Locked Loop” which
issued on November 24, 1998; U.S. Patent No. 5,617,873 for an invention entitled “Non-invasive Method And Apparatus For Monitoring Intracranial Pressure And Pressure Volume Index In Humans,” which issued on April 8, 1997;
U.S. Patent No. 6,413,227 for an invention entitled “Method And Apparatus For Assessment Of Changes In Intracranial Pressure,” which issued on July 2, 2002; U.S. Patent No. 6,475,147 for an invention entitled
“Ultrasonic Apparatus And Technique To Measure Changes In Intracranial Pressure,” which issued on November 5, 2002; U.S. Patent No. 6,761,695 for an invention entitled “Method and Apparatus for Non-Invasive Measurement of
Changes in Intracranial Pressure,” which issued on July 13, 2004; U.S. Patent No. 6,746,410 for an invention entitled “Method And Apparatus For Determining Changes In Intracranial Pressure Utilizing Measurement Of The
Circumferential Expansion Or Contraction Of A Patient’s Skull,” which issued on June 8, 2004; U.S. Patent No. 6,740,048 for an invention entitled “Non-Invasive Method Of Determining Diastolic Intracranial Pressure,”
which issued on May 25, 2004; U.S. Patent No. 6,773,407 for an invention entitled “Non-Invasive Method of Determining Absolute Intracranial Pressure,” which issued on August 10, 2004; U.S. Patent Application
No. 10/805,816, filed on March 22, 2004, entitled “Ultrasonic Apparatus and Method to Assess Compartment Syndrome;” and U.S. Patent Application No. 10/911,755 filed on August 2, 2004, entitled “Method and Apparatus
to Assess Compartment Syndrome;” and PCT Patent Application Number PCT/US02/37580, filed on November 22, 2002, entitled “Method and Apparatus for Non-Invasive Measurement of Changes in Intracranial Pressure.” 
  
 WHEREAS, U.S. Patent Application No. 10/911,755, entitled,
“Method and Apparatus to Assess Compartment Syndrome” is jointly owned by LICENSOR and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (hereinafter “JOINT OWNER”), having a system-wide business 
  

 -1- 

 address of 1111 Franklin Street, Oakland, CA, (hereinafter LICENSOR and JOINT OWNER collectively referred to as JOINT
OWNERS); and JOINT OWNERS have entered into an Agreement in regard to this jointly owned invention(s), entitled: “AGREEMENT BETWEEN THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CONCERNING
LICENSING OF ‘ULTRASONIC APPARATUS AND METHOD TO ASSESS COMPARTMENT SYNDROME’” (hereinafter the “JOINT OWNERSHIP AGREEMENT”) in which The REGENTS OF THE UNIVERSITY OF CALIFORNIA, designates LICENSOR as the primary
negotiating and commercializing agent for any license involving the subject jointly owned invention(s); 
  
 WHEREAS, LICENSOR and LICENSEE agree that the JOINT OWNERSHIP AGREEMENT between JOINT OWNERS is incorporated into this License Agreement by
reference (Appendix B); 
  
 WHEREAS, LICENSEE, in
consideration of the grant of a license under U.S. Patent Nos. 5,150,620; 5,214,955; 5,617,873; 5,841,032; 6,413,227; 6,475,147; 6,740,048; 6,746,410; 6,761,695; and 6,773,407; U.S. Patent Application Nos. 10/805,816 and 10/911,755; and any national
or regional Patent Application(s) that rely on PCT Patent Application Number PCT/US02/37580, will pay royalties, make all necessary capital investments, and achieve PRACTICAL APPLICATION of the invention; and, 
  
 WHEREAS, LICENSOR has determined that the granting of a license to
LICENSEE under U.S. Patent Nos. 5,150,620; 5,214,955; 5,617,873; 5,841,032; 6,413,227; 6,475,147, 6,740,048; 6,746,410; 6,761,695; and 6,773,407; U.S. Patent Application Nos. 10/805,816 and 10/911,755; and any national or regional Patent
Application(s) that rely on PCT Patent Application Number PCT/US02/37580 will provide the necessary incentive for LICENSEE to achieve the desired early PRACTICAL APPLICATION of the invention and the granting of such license to LICENSEE will
therefore be in the public interest; 
  
 NOW, THEREFORE, in
accordance with said Patent Licensing Regulations, and in consideration of the foregoing and of the terms hereinafter contained in this AGREEMENT, the LICENSOR and LICENSEE agree as set forth below: 
  
 ARTICLE I 
  
 Definitions 
  
 “ACCOUNTING PERIOD” shall mean the period of time for which
royalties are calculated. The first ACCOUNTING PERIOD will begin on the LICENSE COMMENCEMENT DATE and end on December 31, 2004. Each subsequent ACCOUNTING PERIOD shall begin on the first day and end on the last day of each subsequent calendar
year. The last ACCOUNTING PERIOD shall end on the LICENSE EXPIRATION DATE. 
  
 “BREACH” shall mean (a) a violation or nonperformance by a PARTY of a MATERIAL term, condition, covenant or warranty herein, or (b) a misrepresentation made hereunder or (c) a
misrepresentation by LICENSEE to induce LICENSOR to enter into this AGREEMENT (also see “MATERIAL”). 
  

 -2- 

 “BREACHING PARTY” shall mean the PARTY in BREACH, as used in Section 18.2. 
  
 “GROSS SALES” shall mean either the total amount invoiced by or for
LICENSEE, and, in the event that some or all of the amount invoiced by LICENSEE is in the form of non-monetary remuneration, then the equivalent dollar value sum of such remuneration, for all disposals (i.e., sales, uses, including uses by LICENSEE,
leases, transfers, etc.) of ROYALTY-BASE PRODUCTS, ROYALTY-BASE SERVICES and ROYALTY-BASE PROCESSES for consideration determined in, or as if in, an arm’s length transaction. 
  
 “INSOLVENT” shall mean that LICENSEE has either ceased to pay its debts (which may include failure to pay royalty
payments under this AGREEMENT) in the ordinary course of business or cannot pay its debts as they fall due or is insolvent within the meaning of the Federal Bankruptcy Code (11 U.S.C. § 101 (31)). 
  
 “LICENSE COMMENCEMENT DATE” shall mean the date that the last PARTY
has executed this AGREEMENT. 
  
 “LICENSE EXPIRATION
DATE” shall mean the last day that this AGREEMENT is in effect. 
  
 “LICENSE TERM” shall mean the period of time starting with the LICENSE COMMENCEMENT DATE and ending with the LICENSE EXPIRATION DATE. 
  
 “LICENSED AREA” shall mean the United States of America, its territories, and its possession; and any national or regional area in the world
that is covered by a LICENSED PATENT or LICENSED PATENT APPLICATION. 
  
 “LICENSED FIELD OR EMBODIMENT(S)” shall mean all medical applications for assessing and measuring: (1) intracranial pressure, and (2) Compartment Syndrome. 
  
 “LICENSED INVENTION” shall mean the inventions described in the LICENSED PATENT APPLICATION and as subsequently
defined by the claims of the corresponding LICENSED PATENT and as may be further limited by ARTICLE II, and shall mean the inventions defined by the claims of the LICENSED PATENT and as may be further limited by ARTICLE II. 
  
 “LICENSED PATENT” shall mean any patents maturing from any LICENSED
PATENT APPLICATION, and shall mean United States Patent Nos. 5,150,620; 5,214,955; 5,617,873; 5,814,033 ; 6,413,227; 6,475,147; 6,740,048; 6,746,410; and 6,761,695, and shall include any corresponding reissue patents, re-examinations and extensions
of such LICENSED PATENT; modifications of said LICENSED PATENT by means of certificates of correction or reexamination certificates. 
  
 “LICENSED PATENT APPLICATION” shall mean United States Patent Application Nos. 10/263,286; 10/805,816 and 10/911,755; and any national or
regional Patent Application(s) that rely 
  

 -3- 

 on PCT Patent Application Number PCT/US02/37580; as well as any continuation or divisional patent applications derived
from these applications (specifically excluding any patent applications containing new matter). 
  
 “MATERIAL,” with respect to a particular matter (e.g., a BREACH), shall mean that the matter is shown to affect adversely (a) the rights
and benefits of the other PARTY under this AGREEMENT; or (b) the ability of the other PARTY to perform its obligations hereunder; and, in either case, to such a degree that a reasonable person in the management of his or her own affairs would
be more likely than not to decline to enter into this AGREEMENT in view of the matter in question. 
  
 “NET SALES” as to ROYALTY-BASE PRODUCTS and ROYALTY-BASE SERVICES shall mean GROSS SALES, less allowances for returns and less (to the extent
separately stated, and not charged to the customer or others, on the invoices): (1) regular trade and quantity discounts; (2) insurance and shipping charges from the point of origin; (3) duties, tariffs, and other customs charges; and
(4) sales, use, value added, and similar taxes. In the case of a sale or other disposition of ROYALTY-BASE PRODUCTS or ROYALTY-BASE SERVICES which are transferred to a purchaser who does not deal at arm’s length, or transferred or
otherwise disposed of for other than monetary consideration (including allocations to LICENSEE’S own beneficial use), NET SALES shall be calculated in accordance with Section 7.6 of this AGREEMENT. As to ROYALTY-BASE PROCESSES, “NET
SALES” shall mean GROSS SALES derived from the use, application, lease, transfer, or other utilization of the ROYALTY-BASE PROCESSES, less allowances for returns and less (to the extent separately stated, and not charged to the customer or
others, on the invoices): i) regular trade and quantity discounts; ii) insurance; iii) duties, tariffs, and other customs charges; and iv) use, value added, sales, and similar taxes. In the case of a use of ROYALTY-BASE PROCESSES for
the benefit of a purchaser who does not deal at arm’s length, or for other than monetary consideration (including LICENSEE’S own beneficial uses), NET SALES shall be calculated in accordance with Section 7.6 of this AGREEMENT.

  
 “NONBREACHING PARTY” shall mean the PARTY not in
BREACH, as used in Section 18.2. 
  
 “PARTY” shall
mean a party to this AGREEMENT. 
  
 “PERSON” shall mean
a natural person; a corporation (for profit or not-for-profit); an association; a partnership (general or limited); a joint venture; a trust; a government or political department, subdivision, or agency; or any other entity. 
  
 “PRACTICAL APPLICATION” shall mean, with respect to the LICENSED
INVENTION, to reduce it to practice and to commercialize it, i.e., to manufacture it in the case of a composition or product, to practice it in the case of a process or method, or to operate it in the case of a machine or system; and, in each case,
under such conditions as to establish: i) that a market for the LICENSED INVENTION has been created, and to the extent practicable, that a market has been created in the United States; ii) that it is being utilized; iii) that its
benefits are, to the extent permitted by law or Government regulations, available to the public on reasonable terms; and iv) that market demand, at least in the United States, shall be reasonably met. 
  

 -4- 

 “ROYALTY-BASE PROCESSES” shall include: (i) any and all processes or methods which employ
or are implemented by the practice of the LICENSED INVENTION, or (ii) the steps of any processes or method used, leased, transferred, or otherwise practiced by LICENSEE or its SUBLICENSEES that is covered by or included within the LICENSED
INVENTION; and shall also include other processes or method steps not covered by or within any of the claims of the LICENSED INVENTION that LICENSEE or its SUBLICENSEES, would not have used, leased, transferred, or otherwise utilized but for the
use, lease, transfer, or other disposition of at least one of the LICENSED INVENTION. 
  
 “ROYALTY-BASE PRODUCTS” shall include: i) the components of an article sold, used, leased, transferred, or otherwise disposed of by LICENSEE or its SUBLICENSEES, that are covered by or included within the
LICENSED INVENTION; and ii) other components of the item not covered by or within the LICENSED INVENTION that LICENSEE or its SUBLICENSEE would not have sold, used, leased, transferred, or otherwise disposed of but for the sale, use, lease,
transfer, or other disposition of the LICENSED INVENTION. 
  
 “ROYALTY-BASE SERVICES” shall include any services sold, used, leased, rented, transferred, or otherwise disposed of by LICENSEE or SUBLICENSEE, or their agents, which use or employ the LICENSED INVENTION. 
  
 “SUBLICENSEE” shall mean any PERSON who has the right, granted by
LICENSEE, to make, use, or sell the LICENSED INVENTION. 
  
 “THIRD PARTIES” shall mean PERSONS other than the LICENSOR and the LICENSEE. 
  
 ARTICLE II 
  
 License
Grant 
  
 2.1 LICENSOR hereby grants to LICENSEE a terminable,
royalty-bearing, exclusive license to practice, i.e., to make, have made, use, offer to sell, sell, transfer, or dispose of, the LICENSED INVENTION as limited to the LICENSED AREA and as may be limited to a LICENSED FIELD OR EMBODIMENT(S), as
defined in ARTICLE I. 
  
 2.2 LICENSOR, upon request, will
use reasonable efforts to grant LICENSEE, in accordance with 37 CFR 404, a license to practice any inventions assigned to LICENSOR, without which license or licenses, the practice of the LICENSED INVENTION would result in infringement. The grant of
said license or licenses shall be limited, however, to the extent necessary to practice the LICENSED INVENTION. There will be no such grant where said inventions are licensed exclusively. 
  
 2.3 Notwithstanding anything to the contrary in this AGREEMENT, LICENSEE shall take the license granted in this
ARTICLE II subject to any outstanding licenses or other rights in THIRD PARTIES under agreements executed by LICENSOR prior to the LICENSE COMMENCEMENT DATE. 
  

 -5- 

 2.4 LICENSOR reserves an irrevocable, royalty-free right to practice and have practiced the LICENSED
INVENTION, and any other inventions as provided in Section 2.2, throughout the world by or on behalf of the Government of the United States and on behalf of any foreign government pursuant to any existing or future treaty or agreement with the
United States. 
  
 2.5 JOINT OWNER expressly reserves the right to
use the jointly owned invention(s) and associated, non-NASA owned, technology for educational and research purposes. 
  
 2.6 LICENSOR intends to file a European Patent Application corresponding to PCT Application Number PCT/US02/37580, entitled “Method and Apparatus for
Non-Invasive Measurement of Changes in Intracranial Pressure,” To conserve costs, LICENSOR also intends to file such application directly through a foreign associate. LICENSEE agrees to pay timely the foreign associate, upon receipt of billing,
the official fees (including maintenance fees) and the foreign associate’s fees for assisting in prosecution of the European Patent Application. While LICENSOR will control prosecution, nevertheless, LICENSOR will use reasonable efforts to
provide LICENSEE assurance of LICENSEE’S involvement in cost containment as it relates to this European patent application. 
  
 ARTICLE III 
  
 Sublicenses 
  
 3.1 Upon written approval by LICENSOR, LICENSEE may grant a written royalty-bearing, sublicense under the license granted in ARTICLE II provided that it submits to LICENSOR a written request, in advance, for permission to grant the
sublicense, including with said request a copy of the proposed sublicense. The proposed sublicense shall refer to and be generally consistent with this AGREEMENT and shall include the rights reserved by LICENSOR under Section 2.4 and JOINT
OWNER under Section 2.5. The proposed sublicense shall include the condition that the sublicense shall automatically terminate upon the revocation or termination of this AGREEMENT. 
  
 3.2 LICENSEE shall furnish LICENSOR with a copy of the sublicense, consistent with the proposed sublicense approved by
LICENSOR and executed by both LICENSEE and its SUBLICENSEE, within fifteen (15) days after the grant of the sublicense by LICENSEE. 
  
 3.3 LICENSEE shall submit to LICENSOR, for advance approval, any proposed modification of a sublicense. LICENSEE shall also submit to LICENSOR a copy of
the sublicense modification (either as an addendum or a new sublicense), consistent with the proposed sublicense modification and executed by both LICENSEE and its SUBLICENSEE, within fifteen (15) days after the effective date of the sublicense
modification. 
  
 3.4 The granting of a sublicense by LICENSEE
shall not operate to relieve LICENSEE from any of its obligations under this AGREEMENT. 
  
 3.5 LICENSEE shall be responsible for and remit royalties based upon its SUBLICENSEE’S activities as if said activities were its own. 
  

 -6- 

 ARTICLE IV 
  
 Term of License 
  
 4.1 Unless either PARTY terminates this Agreement in accordance with Article XIX at an earlier date, the license granted in ARTICLE II will be
in effect for a LICENSE TERM that is equal to the unexpired term of the last patent to be in effect of the patent(s) encompassed under the definition of LICENSED PATENT. Except as may be expressly provided otherwise herein or agreed to in writing by
LICENSOR, the license shall expire automatically at the end of the LICENSE TERM without notice to LICENSEE. 
  
 ARTICLE V 
  
 Practical Application 
  
 5.1 LICENSEE shall
achieve PRACTICAL APPLICATION of a LICENSED INVENTION within [****] of the LICENSE COMMENCEMENT DATE and in accordance with the schedule set forth in the APPENDIX A to this AGREEMENT and incorporated into this AGREEMENT. LICENSEE shall notify
LICENSOR within 30 days of achieving PRACTICAL APPLICATION that PRACTICAL APPLICATION has been achieved. LICENSEE shall also provide evidence to verify the achievement. 
  
 5.2 LICENSEE, once PRACTICAL APPLICATION of the LICENSED INVENTION is achieved, shall thereafter maintain it throughout the
LICENSE TERM. 
  
 5.3 After [****] from the LICENSE
COMMENCEMENT DATE, and at LICENSOR’S sole discretion, LICENSOR may unilaterally modify this Agreement to revoke the license to any LICENSED INVENTION, as defined by the claims of a LICENSED PATENT, or as described by a LICENSED PATENT
APPLICATION, for which PRACTICAL APPLICATION has not been achieved by LICENSEE. Nothing in Section 5.3 is to be interpreted in any manner as to affect or alter any dates, deadlines, schedules or remedies specifically set out elsewhere in this
Agreement or the Appendix thereto. 
  
 5.4 Should LICENSOR revoke
a license to one or more LICENSED INVENTION pursuant to Section 5.3, LICENSOR shall then be free to license the revoked LICENSED INVENTIONS as well as certain potentially non-revoked LICENSED INVENTIONS, namely, those defined by the claims of
U.S. Patent No. 5,214,955 entitled “Constant Frequency Pulsed Phase-Lock Measuring Device,” U.S. Patent No. 5,150,620 entitled “Method of Recertifying Load Bearing Members,” and U.S. Patent No. 5,841,032 entitled
“Variable and Fixed Frequency Pulsed Phase-Locked Loop,” in the LICENSED FIELD or EMBODIMENT(S), to any THIRD PARTY which licenses one or more of the revoked LICENSED INVENTIONS. Such a THIRD PARTY license agreement shall not be a breach
of this AGREEMENT. 
  

 -7- 

 ARTICLE VI 
  
 United States Manufacture 
  
 6.1 LICENSEE agrees that any products embodying the LICENSED INVENTION or produced through the use of the LICENSED INVENTION shall be reduced to practice
and manufactured substantially in the United States, in accordance with 35 U.S.C. 209(b). 
  
 6.2 LICENSEE shall make a bona fide attempt to use or sell the LICENSED INVENTION in the United States. 
  
 6.3 LICENSEE shall promptly report to LICENSOR its discontinuance of making the benefits of the LICENSED INVENTION available to the public. 
  
 ARTICLE VII 
  
 Royalty and Payment 
  
 7.1 For purposes of Article VII, the term ROYALTY-BASE PRODUCTS shall
include ROYALTY-BASE SERVICES and ROYALTY-BASE PROCESSES. 
  
 7.2
In consideration of the license granted in ARTICLE II, LICENSEE shall remit to JOINT OWNERS a nonrefundable license fee in the amount of [****] upon the execution of this AGREEMENT by LICENSEE, and an additional [****] due two
years from the execution of this AGREEMENT by the LICENSEE. This fee is to be distributed in accordance with Section 7.8. 
  
 7.3 LICENSEE agrees to pay JOINT OWNERS a running royalty of [****] per LICENSED INVENTION used, with a maximum royalty of [****] and a
minimum royalty of [****] of the NET SALES of ROYALTY-BASE PRODUCTS. The running royalty shall be remitted to JOINT OWNERS within 30 days of the end of every ACCOUNTING PERIOD, i.e., within 30 days after the last day of December of each
year. These running royalties are to be distributed in accordance with Section 7.8. 
  
 7.4 LICENSEE agrees to pay JOINT OWNERS minimum annual royalties of [****] for the fourth ACCOUNTING PERIOD (i.e., January-December 2007), [****] for the fifth ACCOUNTING PERIOD, and [****]
for the sixth and all subsequent ACCOUNTING PERIODS. The minimum annual royalties shall be remitted within 30 days of the end of each ACCOUNTING PERIOD. These minimum annual royalties are to be distributed in accordance with Section 7.8.

  
 7.5 For any particular ACCOUNTING PERIOD, the running
royalties specified in Section 7.3 shall be credited against the minimum royalty specified in Section 7.4. 
  
 7.6 LICENSEE agrees that in the event any ROYALTY-BASE PRODUCTS shall be sold, transferred, or disposed of, to a third-party for purposes of resale in a
transaction that does not represent an arm’s length transaction, then the royalties to be paid under this AGREEMENT for the 

  

 -8- 

 
ROYALTY-BASE PRODUCTS shall be based upon the NET SALES of the ROYALTY-BASE PRODUCTS by the third-party, rather than upon the NET SALES of the LICENSEE. In
the event ROYALTY-BASE PRODUCTS are sold, transferred, or disposed of, to a third-party in a transaction that does not represent an arm’s length transaction, and the purpose is not resale, then NET SALES shall be calculated as if the
ROYALTY-BASE PRODUCTS had been sold, transferred, or disposed of at the same prices as those charged to outside concerns buying similar merchandise in similar amounts under similar circumstances. Examples of transactions that do not reflect an
arm’s length transaction includes sales, transfers or disposals (1) to any type of organization or individual who owns a controlling interest in LICENSEE by stock ownership or otherwise, (2) to any type of organization in which
LICENSEE shall own, directly or indirectly, a controlling interest by stock ownership or otherwise, or (3) to any type of organization with which, or individual with whom, LICENSEE, its stockholders, or associated companies shall have any
agreement, understanding, or arrangement (such as, among other things, an option to purchase stock, an arrangement involving a division of profits, or special rebates or allowances) without which agreement, understanding, or arrangement, prices paid
by such organization or individual for the ROYALTY-BASE PRODUCTS would be higher than the NET SALES reported by LICENSEE, or if such agreement, understanding, or arrangement results in extending to such organization or individual lower prices for
ROYALTY-BASE PRODUCTS than those charged to outside concerns buying similar merchandise in similar amounts and under similar conditions. 
  
 7.7 Under this Agreement, ROYALTY-BASE PRODUCTS will be considered sold when invoiced, when shipped, or upon receipt of payment, whichever occurs first.

  
 7.8 Royalties shall be paid within thirty (30) days of
the end of each ACCOUNTING PERIOD. Royalties and fees shall be paid by checks denominated in United States dollars. One check should be made payable to the National Aeronautics and Space Administration and one check should be made payable to The
Regents of the University of California. LICENSOR (NASA) shall receive [****] and JOINT OWNER (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) shall receive [****] of the royalties and fees due. The checks shall be mailed by the LICENSEE
directly to each of the JOINT OWNERS at their respective addresses as set forth in ARTICLE XV of this AGREEMENT. The royalty checks shall be mailed concurrently with the report required in ARTICLE VIII of this AGREEMENT. The JOINT
OWNERS’ acceptance of any royalty or fee payment does not eliminate the JOINT OWNERS’ right to contest the accuracy of such payment in the future. 
  
 7.9 LICENSOR shall assess interest, penalties, and administrative costs in accordance with the Federal Claims Collections Standards, 31 C.F.R.
§§ 900-904, on all payments due LICENSOR which are not timely paid by LICENSEE. In addition to these charges, LICENSOR is authorized to charge to LICENSEE the costs of collection and any associated reasonable attorney fees. 
  

 -9- 

 ARTICLE VIII 
  
 Reports 
  
 8.1 For purposes of Article VIII, the term ROYALTY-BASE PRODUCTS shall include ROYALTY-BASE SERVICES and ROYALTY-BASE PROCESSES. 
  
 8.2 LICENSEE shall submit to JOINT OWNERS written reports within thirty
(30) days of the end of every ACCOUNTING PERIOD whether or not royalties are due. Each report shall be submitted concurrently with the royalties required by ARTICLE VII. To ensure that any proprietary information submitted by LICENSEE is
protected to the fullest extent of the law, LICENSEE should mark with a proprietary notice, any portions of the report that is considered proprietary to LICENSEE. 
  
 8.3 Each report shall include the following information: 
  
 (a) With reference to the schedule set forth in APPENDIX A to this AGREEMENT, a narrative description of the steps being
taken to reduce the LICENSED INVENTION to practice. 
  
 (b) With
reference to the schedule set forth in APPENDIX A to this AGREEMENT, a narrative description of the steps being taken to create a market demand for the LICENSED INVENTION, to commercialize the LICENSED INVENTION, and to meet market demand for the
LICENSED INVENTION. 
  
 (c) A narrative description of the
ROYALTY-BASE PRODUCTS currently being offered for sale by LICENSEE and its SUBLICENSEES. Copies of current sales brochures, promotional materials, and price lists shall be included with this description. 
  
 (d) A list of the geographic locations at which the LICENSED INVENTION is
being manufactured. 
  
 (e) The number and type of ROYALTY-BASE
PRODUCTS sold or disposed of by LICENSEE. 
  
 (f) The number and
type of ROYALTY-BASE PRODUCTS sold or disposed of by each SUBLICENSEE (if any). 
  
 (g) The number and type of ROYALTY-BASE PRODUCTS sold or disposed of by each reseller of ROYALTY-BASE PRODUCTS under Section 7.6. 
  
 (h) LICENSEE’S GROSS SALES. 
  
 (i) GROSS SALES for each SUBLICENSEE (if any). 
  

 -10- 

 (j) GROSS SALES for each reseller of ROYALTY-BASE PRODUCTS under Section 7.6. 
  
 (k) LICENSEE’S NET SALES. 
  
 (l) NET SALES for each SUBLICENSEE (if any). 
  
 (m) NET SALES for each reseller of ROYALTY-BASE PRODUCTS under
Section 7.6. 
  
 (n) The amount of royalties due JOINT
OWNERS. 
  
 8.4 Each report shall be accompanied by a
certification by an officer of LICENSEE that the LICENSEE is complying with the terms and conditions of this AGREEMENT and that the responses to each part of Section 8.3 are accurate and complete. 
  
 8.5 LICENSEE shall, upon request, submit to LICENSOR an audited balance sheet
and an audited income statement. Internal audits are permissible, but JOINT OWNERS reserve the right to require an independent audit and additionally reserves the right to approve of the auditor. 
  
 8.6 A final report shall be submitted to JOINT OWNERS by LICENSEE within
thirty (30) days after the termination of this AGREEMENT. 
  
 ARTICLE IX 
  
 Audit Rights 
  
 9.1 LICENSEE shall keep full, true, and accurate records for the purpose of
LICENSOR verifying LICENSEE’S reports to LICENSOR under ARTICLE VIII, verifying LICENSEE’S royalty payments to LICENSOR under ARTICLE VII, and for determining LICENSEE’S activities in general under the AGREEMENT. These
records shall include, but are not limited to, ledgers and journals of account, customer orders, invoices, shipping documents, inventory records, computer records, purchase orders, and tax records. These records, as a whole, shall include
information which will allow, at a minimum, identification of suppliers, customers, items sold or otherwise transferred, and/or services rendered, as well as whether the LICENSEE is operating within the scope of its license. 
  
 9.2 The records described in Section 9.1 shall be available for audit by
LICENSOR, or by an authorized representative of LICENSOR, at all reasonable times for the LICENSE TERM and for three (3) calendar years thereafter. In addition, LICENSEE shall permit inspection by LICENSOR, or by an authorized representative of
LICENSOR, of LICENSEE’S assembly facilities and of LICENSEE’S inventory of ROYALTY-BASE PRODUCTS, including parts, works-in-progress, and finished goods, during any audit by LICENSOR. 
  
 9.3 If LICENSOR, as a result of an audit, discovers an underpayment of
royalties which exceeds [****], then LICENSEE shall reimburse LICENSOR for the cost of the audit, including all related costs of performing the audit (e.g., travel, food, lodging, cost of professional services, etc.), in addition to any
penalties assessed pursuant to Section 7.9. 
  

 -11- 

 ARTICLE X 
  

Marking 
  
 10.1 LICENSEE and all SUBLICENSEE(S) shall mark all ROYALTY-BASE PRODUCTS, or products incorporating ROYALTY-BASE PRODUCTS, in accordance with the
statutes of the United States relating to the marking of patented articles (see 35 U.S.C. § 287). Such marking shall be accomplished by fixing on the article or when, from the character of the article, this cannot be done, by fixing to
it, or to the package wherein one or more of the articles is contained, a label including the notation “Licensed from the National Aeronautics and Space Administration under (insert patent number).” Such marking shall also be included in
all literature and/or advertising materials describing the LICENSED INVENTION. 
  
 ARTICLE XI 
  
 Use of
the JOINT OWNERS’ Names and Disclosure 
  
 11.1 Except as
required by Section 10.1, LICENSEE may use the name of LICENSOR, or the acronym “NASA,” only in truthful statements concerning its relationship with LICENSOR. The letters ‘NASA’ may be used in such truthful statements only
if they are: 
  
 (a) used in their normal typed or printed form;

  
 (b) the same size, color, and intensity as the rest of the
words in a sentence; 
  
 (c) not used in their stylized version as
they appear in the NASA logotype or NASA insignia; and 
  
 (d) not
used to indicate that NASA endorses the LICENSEE’S products, processes, etc. 
  
 11.2 Uses of the letters ‘NASA’, other than those required by Section 10.1 or specified in Section 11.1, shall require the express written approval of LICENSOR. Approval by LICENSOR shall be based
on applicable law (i.e., 42 U.S.C. §§ 2459(b), 2472 (a), and 2473 (c) (l); and 14 CFR § 1221.100 et seq.) and NASA policy governing the use of the letters ‘NASA’ and the words ‘National Aeronautics and Space
Administration’ and shall not be unreasonably withheld. 
  
 11.3 LICENSEE agrees to make copies of its marketing literature available to LICENSOR so that LICENSOR can determine that such use is in accordance with the terms of this ARTICLE. 
  
 11.4 Nothing contained in this Agreement confers any right on LICENSEE to use
in advertising, publicity, or other promotional activities any name, trade name, trademark, or other 
  

 -12- 

 designation of JOINT OWNER (including contraction, abbreviation or simulation of any of the foregoing). Unless required
by law, the use by LICENSEE of the name, “The Regents of the University of California” or the name of any campus of the University Of California is prohibited, without the express written consent of JOINT OWNER. 
  
 11.5 JOINT OWNERS may disclose to the Inventors the terms and conditions of
this Agreement upon their request. If such disclosure is made, UNIVERSITY shall request the Inventors not disclose such terms and conditions to others. 
  
 11.6 JOINT OWNER may acknowledge the existence of this Agreement and the extent of the grant in Article II to third parties, but JOINT OWNER shall
not disclose the financial terms of this Agreement to third parties, except where JOINT OWNER is required by law to do so, such as under the California Public Records Act. 
  
 ARTICLE XII 
  
 Disclaimer of Warranties 
  
 12.1 LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS, IMPLIED, OR STATUTORY, AS TO ANY MATTER WHATSOEVER. 
  
 12.2 In particular, nothing in this AGREEMENT shall be construed as:

  
 (a) A warranty or representation by JOINT OWNERS as to the
validity or scope of any LICENSED PATENT; or 
  
 (b) A warranty or
representation that anything made, used, sold, or otherwise disposed of under any license granted in this AGREEMENT is or will be free from infringement of any type, including patent infringement, copyright infringement, and trademark infringement;
or 
  
 (c) A requirement that LICENSOR shall file any patent
application, secure any patent, or maintain any patent in force, other than the LICENSED PATENT; or 
  
 (d) An obligation to bring or prosecute actions or suits against THIRD PARTIES for infringement; or 
  
 (e) An obligation to furnish any manufacturing or technical information; or,
if any such information is supplied, a warranty or representation that such information is accurate; or 
  
 (f) Conferring a right to use in advertising, publicity or otherwise the name of any inventor of the LICENSED INVENTION or the NASA name, seal, insignia,
logotype or any other adaptation without the prior written consent of LICENSOR (except as otherwise provided in ARTICLE XI); or 
  

 -13- 

 (g) Precluding the export from the United States of ROYALTY-BASE PRODUCTS on which royalties shall have
been paid as provided in ARTICLE VII, provided that the item can be exported under the export control laws of the United States; or 
  
 (h) Granting by implication or estoppel, any licenses or other rights under any patent of JOINT OWNERS or any other PERSON in the United States or any
foreign country; or 
  
 (i) Granting by implication, estoppel, or
otherwise, any licenses or rights under patents or patent applications of JOINT OWNERS other than the LICENSED INVENTION, regardless of whether such other patents or patent applications are dominant, subordinate, or an improvement to the invention
or inventions as claimed, of the LICENSED PATENT or LICENSED PATENT APPLICATION, nor to other applications that did not claim the invention. 
  
 (j) Conferring upon any PERSON (1) any immunity from or defenses under the antitrust laws, (2) any immunity from a charge of patent misuse, or
(3) any immunity from the operation of Federal, State, or other law. 
  
 ARTICLE XIII 
  
 Risk
Allocation and Indemnification 
  
 13.1 JOINT OWNERS make no
representation, extend no warranties of any kind, either express or implied, and assumes no responsibility whatsoever with respect to use, sales, or other disposition by LICENSEE or its vendees or other transferees of products incorporating or made
by the use of (1) the LICENSED INVENTION or (2) information, if any, furnished under this AGREEMENT. 
  
 13.2 LICENSEE shall indemnify JOINT OWNERS, their officers and employees, and hold them harmless against all liabilities, demands, damages, expenses, or
losses including, but not limited to, attorney’s fees, court costs, and the like, arising (1) out of the use by LICENSEE or its transferees of the LICENSED INVENTION or information furnished under this AGREEMENT, or (2) out of any
sale, use, or other disposition by LICENSEE or its transferees of products, processes, or compositions, made by use of such inventions or information. 
  
 13.3 It shall be the sole responsibility of the LICENSEE to ensure that any and all embodiments of the LICENSED INVENTION are safe under all
circumstances. 
  
 13.4 Independent of, severable from, and to be
enforced independently of any other enforceable or unenforceable provision of this AGREEMENT, other than as provided in Sections 13.1 and 13.2, or other than for infringement of one PARTY’S intellectual property rights by another PARTY,
(including any engagement in licensable activities by licenses beyond the scope of the license provided by this AGREEMENT), neither PARTY will be liable to the other PARTY (nor to any THIRD PARTY claiming rights derived from the other PARTY’S
rights) for incidental, consequential, special, punitive, or exemplary damages of any kind, including lost profits, loss of business, or other economic damage, and further including injury to property, as a result of breach of any warranty or other
term of this AGREEMENT, regardless of whether the PARTY liable or allegedly liable was advised, had reason to know, or in fact knew of the possibility thereof. 
  

 -14- 

 ARTICLE XIV 
  
 Patent Validity 
  
 14.1 If, in any proceeding in which the validity, infringement, or priority of invention of any claim of the LICENSED PATENT to LICENSEE is in issue, a
judgment or decree is entered which becomes final (below referred to as a “final judgment”), the construction placed upon any such claim by such final judgment shall thereafter be followed, not only as to such claim but as to all claims to
which such construction applies, with respect to subsequently occurring acts. If such final judgment holds any claim invalid, LICENSEE shall be relieved prospectively (1) from including in its reports ROYALTY-BASE PRODUCTS, ROYALTY-BASE
PROCESSES or ROYALTY-BASE SERVICES sold or otherwise disposed of covered only by such claim or any broader claim to which such final judgment is applicable, and (2) from the performance of those other acts which may be required by this
AGREEMENT only because of any such claim. However, if there are two or more conflicting final judgments with respect to the same claim based on the same grounds or where the same issues were raised, the decision of the higher tribunal shall be
followed, but if the tribunals be of equal dignity, then the decision more favorable to the claim shall be followed. 
  
 14.2 In the event evidentiary material comes to the attention of the LICENSEE which, in the judgment of the LICENSEE, bears on the validity or scope of
any LICENSED PATENT, the LICENSOR will in good faith discuss with the LICENSEE whether such evidentiary material so affects the validity or scope of the LICENSED PATENT to which it is asserted to apply that the terms of the AGREEMENT in respect to
such LICENSED PATENT should be modified. 
  
 14.3 The LICENSEE,
after the LICENSE COMMENCEMENT DATE, may assert the invalidity of any claim in any LICENSED PATENT, if coupled with or followed by: 
  
 (a) Withholding, or notice of intention to withhold, or denial of obligation to pay, royalties otherwise payable under this AGREEMENT in respect to the
LICENSEE’S operations under such claim; or 
  
 (b) Initiation
or participation in a suit challenging or denying the validity of such claim in reference to LICENSEE’S operations under this AGREEMENT, that may, at the option of the LICENSOR, be conclusively presumed to constitute LICENSEE’S
termination, as of the earliest provable date of such withholding, notice, denial, initiation, or participation, of its AGREEMENT including its obligation for payment of royalties due from the date of the termination 
  

 -15- 

 ARTICLE XV 
  
 Points of Contact 
  
 15.1 The following individuals are designated as the points of contact for their respective PARTY and are responsible for keeping this information current
by providing updated information as warranted. These points of contact are the principal representatives of the PARTIES involved in the performance of this AGREEMENT. 
  

			
	LICENSOR (NASA)	  	LICENSEE
		
	 Patent Counsel
	  	 Patents and Licensing

	 NASA Langley Research Center
	  	 Luna Innovations Incorporated

	 Office of Chief Counsel
	  	 2851 Commerce Street

	 Mail Stop 212
	  	 Blacksburg, VA 24060

	 Hampton, VA 23681-2199
	  	 Telephone No.: [****]

	 Telephone No.: [****]
	  	 Facsimile No.:  [****]

	 Facsimile No.:  [****]
	  	 

  
 JOINT OWNER (THE
REGENTS OF THE UNIVERSITY OF CALIFORNIA, REPRESENTED BY ITS SAN DIEGO CAMPUS) 
  
 If sent to JOINT OWNER by mail: 
 University of California, San Diego 
 Technology Transfer & Intellectual Property Services 
 9500 Gilman Drive 
 Mail Code 0910 
 La Jolla, CA 92093-0910 
 Attention: Assistant
Vice Chancellor 
 Telephone No.: [****] 
 Facsimile No.:  [****] 
  
 If sent to JOINT OWNER by courier: 
 University of California, San Diego 
 Technology Transfer & Intellectual Property Services 
 10300 North Torrey Pines Road 
 Torrey Pines Center North, First Floor 
 La Jolla, CA 92037 
 Attention: Assistant Vice
Chancellor 
  

 -16- 

 For wire payments to JOINT OWNER: 
 All payments due UNIVERSITY and made by wire transfers shall include an additional wire transfer fee of twenty-five dollar (US$25) to the amount due. Wire
transfers shall be made using the following information: 
  

			
	UCSD receiving bank name: [****]	  	 
	UCSD bank account no.: [****]	  	 
	UCSD bank routing (ABA) no.: [****]	  	 
	UCSD bank account name: [****]	  	 
	UCSD bank ACH format code: [****]	  	 

  
 UCSD bank address:

 [****] 
 [****]

 [****] 
 [****]

  
 UCSD addendum information: 
 Reference UCSD-TechTIPS Case No.: [****] 
 Department contact: Financial Manager 
 A fax copy of the transaction receipt should be sent to Financial Manager at: [****].

 LICENSEE is responsible for all bank charges of wire transfer funds. 
 The bank charges should not be deducted from total amount due to the JOINT OWNER. 
  
 ARTICLE XVI 
  
 Notices 
  
 16.1 All notices hereunder will be in writing and will be delivered and effective as follows: 
  
 (a) Every notice required or contemplated by this AGREEMENT to be given
either PARTY may be delivered in person or may be sent by commercial courier or U.S. mail, addressed to the PARTY for whom it is intended, at the address specified in ARTICLE XV. 
  
 (b) Any notice will be effective on the date that it is hand delivered or on the fifth business day after it was deposited
with the commercial courier or the U.S. mail. 
  
 (c) As used in
this ARTICLE, a reference to a particular date means the date itself, if a business day, otherwise the first business day after the date. 
  
 ARTICLE XVII 
  
 Infringement 
  
 17.1 If LICENSEE becomes aware of an infringement or has reasonable cause to believe that there has been an infringement of any LICENSED PATENT, LICENSEE shall notify 

  

 -17- 

 
LICENSOR in writing concerning LICENSEE’S knowledge of any infringement or of the reasonable cause for belief of infringement. Such notice should
include: an analysis of how the claims of any LICENSED PATENT read-on the allegedly infringing articles; the identity of the alleged infringers; a statement as to whether the alleged infringers are making, using, or selling the allegedly infringing
articles; a statement describing the extent of the alleged infringement; and a statement which describes and quantifies the harm being suffered by the LICENSEE as a result of the alleged infringement. If such notice and information are furnished,
LICENSOR may volunteer its opinion as to whether reasonable cause exists to believe that there has been an infringement. LICENSEE is authorized under the provisions of Chapter 29 of Title 35, United States Code, or other statutes, (a) to
bring suit in its own name, at its own expense, and on its own behalf, for infringement of the LICENSED PATENT, and (b) in any such suit, to enjoin infringement and to collect for its use, damages, profits and awards of whatever nature,
recoverable from such infringement, subject to payment of royalties due to JOINT OWNERS, and further, (c) to settle any claim or suit for infringement of the LICENSED PATENT, as by granting a sublicense under this AGREEMENT. With respect to the
royalties due to JOINT OWNERS from LICENSEE’S successful infringement action, the parties agree to enter into good faith negotiations to arrive at the appropriate amount of royalties due to JOINT OWNERS. The authority to bring suit is subject
to the continuing right of the United States to bring suit itself or to intervene in LICENSEE’S suit; and, in either event, LICENSEE shall give LICENSOR reasonable notice and assistance. 
  
 ARTICLE XVIII 
  
 Dispute or Breach 
  
 18.1 All disputes concerning the interpretation or application of this
AGREEMENT shall be discussed mutually between the PARTIES. Any disputes that are not disposed of by mutual agreement shall be decided by the NASA Lead Counsel for the Intellectual Property Law Group, or designee, who shall reduce the decision to
writing and mail or otherwise deliver a copy thereof to LICENSEE. LICENSEE may respond to such notice of a decision in accordance with the procedures set forth in Section 19.8. 
  
 18.2 In the event of a BREACH of any provision of this AGREEMENT, the NONBREACHING PARTY shall give the BREACHING PARTY
notice describing the BREACH and stating that the BREACHING PARTY has thirty (30) days after notice of the BREACH to cure the BREACH or show cause why the AGREEMENT should not be terminated. 
  
 18.3 If a provision of this AGREEMENT sets forth a cure period for the BREACH
in question other than thirty (30) days, then that provision shall take precedence over the cure period set forth in Section 18.2. 
  
 18.4 No cure period is required, except as may be otherwise provided in this AGREEMENT, if: 
  
 (a) this AGREEMENT sets forth specific deadline dates for the obligation allegedly breached; or 
  

 -18- 

 (b) this AGREEMENT otherwise states that no cure period is required in connection with the termination in
question. 
  
 18.5 The BREACHING PARTY will be deemed to have
cured such BREACH if within the cure period it takes steps reasonably adequate to alleviate any damage to the NONBREACHING PARTY resulting from the BREACH and to prevent a similar future BREACH. 
  
 ARTICLE XIX 
  
 Termination or Modification 
  
 19.1 The PARTIES may terminate or modify this AGREEMENT by mutual consent
upon such terms as they may agree in writing. 
  
 19.2 Either
PARTY may terminate this AGREEMENT by failing to extend the LICENSE TERM, if an extension is provided for in Section 4.1. 
  
 19.3 Either PARTY may terminate this AGREEMENT upon the discovery by one PARTY of any intentional MATERIAL false statement or misrepresentation made or
submitted by the other PARTY which BREACHES any obligation under the terms of this AGREEMENT or upon the discovery by one PARTY that the other PARTY has committed a MATERIAL BREACH of a provision of the AGREEMENT. 
  
 19.4 LICENSEE may prospectively terminate this AGREEMENT upon ninety
(90) days written notice to LICENSOR. 
  
 19.5 This AGREEMENT
may be terminated by LICENSOR if: 
  
 (a) LICENSOR determines
that LICENSEE has failed or will fail to achieve or maintain PRACTICAL APPLICATION of the LICENSED INVENTION as provided by ARTICLE V. 
  
 (b) LICENSOR determines that LICENSEE has failed or will fail to reduce to practice and substantially manufacture the LICENSED INVENTION in the United
States as provided by Section 6.1 
  
 (c) LICENSOR determines
that LICENSEE has failed or will fail to meet market demand for the LICENSED INVENTION. 
  
 (d) LICENSEE fails to pay royalties or submit reports as provided by ARTICLE VII and VIII. 
  
 (e) LICENSOR determines that such action is necessary to meet the requirements for public use specified by Federal regulations issued after the date of
the license and such requirements are not reasonably satisfied by LICENSEE. 
  

 -19- 

 (f) LICENSEE commits a BREACH of a covenant contained in this AGREEMENT. 
  
 19.6 LICENSOR may terminate this AGREEMENT if LICENSEE becomes
“INSOLVENT.” LICENSEE must notify LICENSOR within thirty (30) days after becoming INSOLVENT. LICENSEE’S failure to conform to this requirement shall be deemed a MATERIAL, incurable BREACH. 
  
 19.7 LICENSEE must promptly inform LICENSOR of its intention to file a
voluntary petition in bankruptcy or of another’s communicated intention to file an involuntary petition in bankruptcy. LICENSOR may terminate this AGREEMENT upon receiving notice of intention to file. LICENSEE’S filing without conforming
to this requirement shall be deemed a MATERIAL, pre-petition incurable BREACH. 
  
 19.8 Before LICENSOR unilaterally modifies, or terminates this AGREEMENT for any cause, LICENSOR will deliver to LICENSEE and all SUBLICENSEES of record a written notice stating LICENSOR’S intention to modify or
terminate the AGREEMENT and the reasons therefor. LICENSEE and SUBLICENSEES of record will be allowed thirty (30) days after: (1) such notice to remedy any BREACH of the AGREEMENT or show cause why the AGREEMENT should not be unilaterally
modified or terminated; or, (2) such notice of a decision regarding a dispute, rendered in accordance with Article 18.1, to rebut such decision. A response to a notice of modification or termination or to a notice of a dispute decision
should be addressed to the General Counsel, National Aeronautics and Space Administration, Washington, DC 20546. The General Counsel will render a determination based on the LICENSEE’S response within a reasonable time. Absent any response from
LICENSEE to the notice regarding the modification, termination and/or dispute decision, the decision by the Lead Counsel for the Intellectual Property Law Group will be final and/or the AGREEMENT will be unilaterally modified or will terminate,
effective thirty-one (31) days from the notice of modification, termination or dispute decision, with no right to appeal under Section 19.9. 
  
 19.9 LICENSEE may appeal in writing to the NASA Administrator, any determination rendered by the General Counsel in accordance with Section 19.8,
within thirty (30) days after delivery of such determination. The notice of appeal and all supporting documentation should be addressed to the Administrator, National Aeronautics and Space Administration, Washington, DC 20546. LICENSEE shall be
afforded an opportunity to be heard and to offer evidence in support of its appeal. The decision on the appeal shall be made by the NASA Administrator or designee, which shall be the final agency decision from which there will be no further right of
administrative appeal. Nothing in this Article shall be interpreted as precluding actions at law. 
  
 19.10 If no action is taken under Section 19.9, then the determination rendered by the General Counsel shall become final within thirty-one
(31) days after delivery of the notice of such determination. 
  
 19.11 All royalties and reports due up to and including the date of termination of this AGREEMENT are due within thirty (30) days of the date of termination. 
  

 -20- 

 ARTICLE XX 
  
 Assignment 
  
 20.1 Upon written approval by LICENSOR, LICENSEE may assign this AGREEMENT provided that LICENSEE submits to LICENSOR, in advance, a written request for
permission to grant the assignment, information that LICENSOR considers necessary to evaluate the proposed assignment, and a copy of the proposed assignment. If LICENSOR approves the assignment as being consistent with the Government’s
interests, the PARTIES and the assignee will be required to execute a novation agreement. At a minimum, the novation agreement will provide that LICENSEE waives all rights under the license, the assignee assumes all obligations under the AGREEMENT
and that LICENSOR recognizes the assignee as the successor in interest to the AGREEMENT. 
  
 ARTICLE XXI 
  
 Governing Law 
  
 21.1 This AGREEMENT will be
interpreted and enforced in accordance with United States federal law. 
  
 ARTICLE XXII 
  
 Independent Entities

  
 22.1 The Parties are separate and independent entities.
Except as may be expressly and unambiguously provided in this AGREEMENT, no partnership or joint venture is intended to be created by this AGREEMENT, nor any principal-agent or employer-employee relationship. 
  
 22.2 Except to the extent expressly provided in this AGREEMENT, neither PARTY
has, and neither PARTY shall attempt to assert, the authority to make commitments for or to bind the other PARTY to any obligation. 
  
 ARTICLE XXIII 
  
 Effect of Partial Invalidity 
  
 23.1 If any one of more of the provisions of this AGREEMENT should be ruled wholly or partly invalid or unenforceable by a court or other government body of competent jurisdiction, and as long as the fundamental
objectives of the AGREEMENT can be carried out, then: 
  
 (a) the
validity and enforceability of all provisions of this AGREEMENT not ruled to be invalid or unenforceable will be unaffected; 
  

 -21- 

 (b) the provision(s) held wholly or partly invalid or unenforceable will be deemed to be amended, and the
court or other government body is authorized to reform the provision(s), to the minimum extent necessary to render them valid and enforceable in conformity with the PARTIES’ intent as manifested herein; and 
  
 (c) if the ruling, and/or the controlling principle of law or equity leading
to the ruling, is subsequently overruled, modified, or amended by legislative, judicial, or administrative action, then the provision(s) in question, as originally set forth in this AGREEMENT, will be deemed to be valid and enforceable to the
maximum extent permitted by the new controlling principle of law or equity. 
  
 ARTICLE XXIV 
  
 Nonwaiver 
  
 24.1 The failure of either PARTY at
any time to require performance by the other PARTY of any provisions of this AGREEMENT shall in no way affect the right of such PARTY to require future performance of that provision. Any waiver by either PARTY of any BREACH of any provision of this
AGREEMENT shall not be construed as a waiver of any continuing or succeeding BREACH of such provision, a waiver of the provision itself, or a waiver of any right under this AGREEMENT. 
  
 ARTICLE XXV 
  
 Entire Agreement 
  
 25.1 Except as may be expressly provided otherwise herein, this AGREEMENT constitutes the entire agreement between the PARTIES concerning the subject
matter thereof. No prior or contemporaneous representations, inducements, promises, or agreements, oral or otherwise, between the PARTIES with reference thereto will be of any force or effect. This AGREEMENT may only be modified by written agreement
of the PARTIES. 
  
 ARTICLE XXVI 
  
 Article Headings 
  
 26.1 The ARTICLE headings contained in this AGREEMENT are for reference
purposes only and shall not in any way control the meaning or interpretation of this AGREEMENT. 
  

 -22- 

 ARTICLE XXVII 
  
 Counterparts 
  
 27.1 This AGREEMENT may be executed in separate counterparts, each of which so executed and delivered shall constitute an original, but all such
counterparts shall together constitute one and the same instrument. Any such counterpart may comprise one or more duplicates or duplicate signature pages, any of which may be executed by less than all of the PARTIES, provided that each PARTY
executes at least one such duplicate or duplicate signature page. The PARTIES stipulate that a photostatic copy of an executed original will be admissible in evidence for all purposes in any proceeding as between the PARTIES. 
  
 ARTICLE XXVIII 
  
 Acceptance 
  
 28.1 In witness whereof, each PARTY has caused this AGREEMENT to be executed
by its duly authorized representatives: 
  

									
	LICENSOR:	 	 	 	LICENSEE:
			
	 National Aeronautics and Space Administration
  
	 	 	 	 Luna Innovations Incorporated
  

					
	By:	 	 /s/    Michael C. Wholley

	 	 	 	By:	 	 /s/    Michael F. Gunther

	 	 	 Michael C. Wholley
 General Counsel
	 	 	 	 	 	 Michael F. Gunther
 Vice President Operations

			
	  
 Date:
October 28, 2004
	 	 	 	  
 Date: September
24, 2004

  

 -23- 

 APPENDIX A 
  
 Luna License Technical and Commercialization Milestones 
  
 [****] 
  

 -24- 

 APPENDIX B 
  
 Copy of Joint Ownership Agreement DE-382 Between The 
 National Aeronautics and space Administration and the 
 Regents of the University of
California Concerning 
 Licensing of “Ultrasonic Apparatus and Method to Assess 
 Compartment Syndrome” 
  
 [****] 
  

 -1-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}]]